JAMA Neurology,
Journal Year:
2015,
Volume and Issue:
72(5), P. 511 - 511
Published: March 16, 2015
Typical
cognitive
aging
may
be
defined
as
age-associated
changes
in
performance
individuals
who
remain
free
of
dementia.
Ideally,
the
full
adult
age
spectrum
should
included
to
assess
brain
imaging
findings
associated
with
typical
aging.To
compare
age,
sex,
and
APOE
ε4
effects
on
memory,
structure
(adjusted
hippocampal
volume
[HVa]),
amyloid
positron
emission
tomography
(PET)
cognitively
normal
aged
30
95
years
old.Cross-sectional
observational
study
(March
2006
October
2014)
at
an
academic
medical
center.
We
studied
1246
individuals,
including
1209
participants
50
old
enrolled
a
population-based
37
self-selected
volunteers
49
old.Memory,
HVa,
PET.Overall,
memory
worsened
from
through
90s.
The
HVa
gradually
mid-60s
more
steeply
beyond
that
age.
median
PET
was
low
until
70
increased
thereafter.
Memory
worse
men
than
women
overall
(P
<
.001)
specifically
40
years.
lower
60
There
no
sex
difference
any
Within
each
were
not
different
by
status
From
onward,
carriers
had
significantly
greater
noncarriers.
However,
ages
which
10%
population
positive
57
for
64
noncarriers.Male
is
among
while
not.
In
contrast,
(from
onward),
Worsening
occur
earlier
abnormal
PET.
Therefore,
neuropathological
processes
other
β-amyloidosis
must
underlie
declines
function
middle
Our
are
consistent
model
late-onset
Alzheimer
disease
arises
later
life
background
preexisting
structural
decline
β-amyloid
deposits.
Alzheimer s & Dementia,
Journal Year:
2018,
Volume and Issue:
14(4), P. 535 - 562
Published: April 1, 2018
In
2011,
the
National
Institute
on
Aging
and
Alzheimer's
Association
created
separate
diagnostic
recommendations
for
preclinical,
mild
cognitive
impairment,
dementia
stages
of
disease.
Scientific
progress
in
interim
led
to
an
initiative
by
update
unify
2011
guidelines.
This
unifying
is
labeled
a
"research
framework"
because
its
intended
use
observational
interventional
research,
not
routine
clinical
care.
Research
Framework,
disease
(AD)
defined
underlying
pathologic
processes
that
can
be
documented
postmortem
examination
or
vivo
biomarkers.
The
diagnosis
based
consequences
(i.e.,
symptoms/signs)
this
research
framework,
which
shifts
definition
AD
living
people
from
syndromal
biological
construct.
framework
focuses
with
biomarkers
persons.
Biomarkers
are
grouped
into
those
β
amyloid
deposition,
tau,
neurodegeneration
[AT(N)].
ATN
classification
system
groups
different
(imaging
biofluids)
process
each
measures.
AT(N)
flexible
new
added
three
existing
groups,
biomarker
beyond
when
they
become
available.
We
focus
as
continuum,
staging
may
accomplished
using
continuous
However,
we
also
outline
two
categorical
schemes
severity
impairment:
scheme
traditional
categories
six-stage
numeric
scheme.
It
important
stress
seeks
create
common
language
investigators
generate
test
hypotheses
about
interactions
among
(denoted
biomarkers)
symptoms.
appreciate
concern
biomarker-based
has
potential
misused.
Therefore,
emphasize,
first,
it
premature
inappropriate
general
medical
practice.
Second,
should
used
restrict
alternative
approaches
hypothesis
testing
do
There
will
situations
where
available
requiring
them
would
counterproductive
specific
goals
(discussed
more
detail
later
document).
Thus,
considered
template
all
age-related
impairment
dementia;
rather,
applied
fit
purpose
study.
Importantly,
examined
diverse
populations.
Although
possible
β-amyloid
plaques
neurofibrillary
tau
deposits
causal
pathogenesis,
these
abnormal
protein
define
unique
neurodegenerative
disorders
lead
dementia.
envision
defining
construct
enable
accurate
characterization
understanding
sequence
events
associated
AD,
well
multifactorial
etiology
approach
precise
trials
pathways
targeted
appropriate
people.
Circulation,
Journal Year:
2020,
Volume and Issue:
141(9)
Published: Jan. 29, 2020
The
American
Heart
Association,
in
conjunction
with
the
National
Institutes
of
Health,
annually
reports
on
most
up-to-date
statistics
related
to
heart
disease,
stroke,
and
cardiovascular
risk
factors,
including
core
health
behaviors
(smoking,
physical
activity,
diet,
weight)
factors
(cholesterol,
blood
pressure,
glucose
control)
that
contribute
health.
Statistical
Update
presents
latest
data
a
range
major
clinical
circulatory
disease
conditions
(including
congenital
rhythm
disorders,
subclinical
atherosclerosis,
coronary
failure,
valvular
venous
peripheral
artery
disease)
associated
outcomes
quality
care,
procedures,
economic
costs).The
through
its
Statistics
Committee,
continuously
monitors
evaluates
sources
stroke
United
States
provide
current
information
available
annual
Update.
2020
is
product
full
year's
worth
effort
by
dedicated
volunteer
clinicians
scientists,
committed
government
professionals,
Association
staff
members.
This
edition
includes
monitoring
benefits
population,
metrics
assess
monitor
healthy
diets,
an
enhanced
focus
social
determinants
health,
global
burden
further
evidence-based
approaches
changing
behaviors,
implementation
strategies,
implications
Association's
Impact
Goals.Each
26
chapters
focuses
different
topic
statistics.The
represents
critical
resource
for
lay
public,
policy
makers,
media
clinicians,
healthcare
administrators,
researchers,
advocates,
others
seeking
best
these
conditions.
Circulation,
Journal Year:
2021,
Volume and Issue:
143(8)
Published: Jan. 27, 2021
The
American
Heart
Association,
in
conjunction
with
the
National
Institutes
of
Health,
annually
reports
most
up-to-date
statistics
related
to
heart
disease,
stroke,
and
cardiovascular
risk
factors,
including
core
health
behaviors
(smoking,
physical
activity,
diet,
weight)
factors
(cholesterol,
blood
pressure,
glucose
control)
that
contribute
health.
Statistical
Update
presents
latest
data
on
a
range
major
clinical
circulatory
disease
conditions
(including
congenital
rhythm
disorders,
subclinical
atherosclerosis,
coronary
failure,
valvular
venous
peripheral
artery
disease)
associated
outcomes
quality
care,
procedures,
economic
costs).The
through
its
Statistics
Committee,
continuously
monitors
evaluates
sources
stroke
United
States
provide
current
information
available
annual
Update.
2021
is
product
full
year's
worth
effort
by
dedicated
volunteer
clinicians
scientists,
committed
government
professionals,
Association
staff
members.
This
edition
includes
monitoring
benefits
population,
an
enhanced
focus
social
determinants
health,
adverse
pregnancy
outcomes,
vascular
contributions
brain
global
burden
further
evidence-based
approaches
changing
disease.Each
27
chapters
focuses
different
topic
statistics.The
represents
critical
resource
for
lay
public,
policy
makers,
media
clinicians,
care
administrators,
researchers,
advocates,
others
seeking
best
these
conditions.
Alzheimer s & Dementia,
Journal Year:
2016,
Volume and Issue:
12(3), P. 292 - 323
Published: March 1, 2016
During
the
past
decade,
a
conceptual
shift
occurred
in
field
of
Alzheimer's
disease
(AD)
considering
as
continuum.
Thanks
to
evolving
biomarker
research
and
substantial
discoveries,
it
is
now
possible
identify
even
at
preclinical
stage
before
occurrence
first
clinical
symptoms.
This
AD
has
become
major
focus
postulates
that
early
intervention
may
offer
best
chance
therapeutic
success.
To
date,
very
little
evidence
established
on
this
"silent"
disease.
A
clarification
needed
about
definitions
lexicon,
limits,
natural
history,
markers
progression,
ethical
consequence
detecting
asymptomatic
stage.
article
aimed
addressing
all
different
issues
by
providing
for
each
them
an
updated
review
literature
evidence,
with
practical
recommendations.
Neurology,
Journal Year:
2016,
Volume and Issue:
87(5), P. 539 - 547
Published: July 2, 2016
Biomarkers
have
become
an
essential
component
of
Alzheimer
disease
(AD)
research
and
because
the
pervasiveness
AD
pathology
in
elderly,
same
biomarkers
are
used
cognitive
aging
research.
A
number
current
issues
suggest
that
unbiased
descriptive
classification
scheme
for
these
would
be
useful.
We
propose
"A/T/N"
system
which
7
major
divided
into
3
binary
categories
based
on
nature
pathophysiology
each
measures.
"A"
refers
to
value
a
β-amyloid
biomarker
(amyloid
PET
or
CSF
Aβ42);
"T,"
tau
(CSF
phospho
tau,
PET);
"N,"
neurodegeneration
neuronal
injury
([(18)F]-fluorodeoxyglucose-PET,
structural
MRI,
total
tau).
Each
category
is
rated
as
positive
negative.
An
individual
score
might
appear
A+/T+/N-,
A+/T-/N-,
etc.
The
A/T/N
includes
new
modality
PET.
It
agnostic
temporal
ordering
mechanisms
underlying
pathogenesis.
all
individuals
any
population
regardless
mix
findings
therefore
suited
studies
aging.
does
not
specify
labels
thus
diagnostic
system.
categorizing
multidomain
at
person
level
format
easy
understand
use.
Given
present
lack
consensus
among
specialists
terminology
across
clinically
normal
dementia
spectrum,
will
broadest
acceptance
if
it
independent
from
one
defined
scheme.
Journal of Alzheimer s Disease,
Journal Year:
2017,
Volume and Issue:
57(4), P. 1105 - 1121
Published: Jan. 6, 2017
Alzheimer's
disease
(AD)
is
a
devastating
neurodegenerative
disorder
without
cure.
Most
AD
cases
are
sporadic
where
age
represents
the
greatest
risk
factor.
Lack
of
understanding
mechanism
hinders
development
efficacious
therapeutic
approaches.
The
loss
synapses
in
affected
brain
regions
correlates
best
with
cognitive
impairment
patients
and
has
been
considered
as
early
that
precedes
neuronal
loss.
Oxidative
stress
recognized
contributing
factor
aging
progression
multiple
diseases
including
AD.
Increased
production
reactive
oxygen
species
(ROS)
associated
age-
disease-dependent
mitochondrial
function,
altered
metal
homeostasis,
reduced
antioxidant
defense
directly
affect
synaptic
activity
neurotransmission
neurons
leading
to
dysfunction.
In
addition,
molecular
targets
by
ROS
include
nuclear
DNA,
lipids,
proteins,
calcium
dynamics
cellular
architecture,
receptor
trafficking
endocytosis,
energy
homeostasis.
Abnormal
metabolism
turn
could
accumulation
amyloid-β
(Aβ)
hyperphosphorylated
Tau
protein,
which
independently
exacerbate
dysfunction
production,
thereby
vicious
cycle.
While
mounting
evidence
implicates
etiology,
clinical
trials
therapies
have
not
produced
consistent
results.
this
review,
we
will
discuss
role
oxidative
AD,
innovative
strategies
evolved
based
on
better
complexity
mechanisms
dual
play
health
disease.
JAMA,
Journal Year:
2015,
Volume and Issue:
313(19), P. 1924 - 1924
Published: May 19, 2015
Cerebral
amyloid-β
aggregation
is
an
early
pathological
event
in
Alzheimer
disease
(AD),
starting
decades
before
dementia
onset.
Estimates
of
the
prevalence
amyloid
pathology
persons
without
are
needed
to
understand
development
AD
and
design
prevention
studies.